ES2967066T3 - Composiciones para su uso como agente profiláctico para aquellos en riesgo de infección de tuberculosis, o como agentes secundarios para tratar pacientes infectados con tuberculosis - Google Patents

Composiciones para su uso como agente profiláctico para aquellos en riesgo de infección de tuberculosis, o como agentes secundarios para tratar pacientes infectados con tuberculosis Download PDF

Info

Publication number
ES2967066T3
ES2967066T3 ES19704653T ES19704653T ES2967066T3 ES 2967066 T3 ES2967066 T3 ES 2967066T3 ES 19704653 T ES19704653 T ES 19704653T ES 19704653 T ES19704653 T ES 19704653T ES 2967066 T3 ES2967066 T3 ES 2967066T3
Authority
ES
Spain
Prior art keywords
tuberculosis
mtbvac
strain
medium
bcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19704653T
Other languages
English (en)
Spanish (es)
Inventor
Montanes Carlos Martin
Anento Juan Ignacio Aguilo
Asensio Jesús Angel Gonzalo
Dessislava Vaneva Marinova
Maiz Santiago Uganda
Sanchez Esteban Rodriguez
Colorado Eugenia Puentes
Alvarez-Santullano Concepción Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofabri S L
Universidad de Zaragoza
Original Assignee
Biofabri S L
Universidad de Zaragoza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofabri S L, Universidad de Zaragoza filed Critical Biofabri S L
Application granted granted Critical
Publication of ES2967066T3 publication Critical patent/ES2967066T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/16—Magnesium; Mg chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/35—Polyols, e.g. glycerin, inositol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES19704653T 2018-02-19 2019-02-19 Composiciones para su uso como agente profiláctico para aquellos en riesgo de infección de tuberculosis, o como agentes secundarios para tratar pacientes infectados con tuberculosis Active ES2967066T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382097 2018-02-19
PCT/EP2019/054106 WO2019158779A1 (en) 2018-02-19 2019-02-19 Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients

Publications (1)

Publication Number Publication Date
ES2967066T3 true ES2967066T3 (es) 2024-04-25

Family

ID=61557215

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19704653T Active ES2967066T3 (es) 2018-02-19 2019-02-19 Composiciones para su uso como agente profiláctico para aquellos en riesgo de infección de tuberculosis, o como agentes secundarios para tratar pacientes infectados con tuberculosis

Country Status (9)

Country Link
US (3) US11826411B2 (https=)
EP (2) EP3755374B1 (https=)
JP (3) JP7388636B2 (https=)
CN (2) CN116751703A (https=)
AU (2) AU2019221709B2 (https=)
BR (1) BR112020016704A2 (https=)
CA (1) CA3091304A1 (https=)
ES (1) ES2967066T3 (https=)
WO (1) WO2019158779A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria
CN113122484B (zh) * 2021-06-03 2023-11-03 郑州安图生物工程股份有限公司 一种非结核分枝杆菌的冻干保护剂及其制备方法和保藏方法
WO2025063217A1 (ja) 2023-09-20 2025-03-27 住友金属鉱山株式会社 赤外線吸収粒子、赤外線吸収粒子分散液、赤外線吸収透明基材、赤外線吸収粒子分散体、赤外線吸収合わせ透明基材

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1108956A (en) * 1964-05-26 1968-04-10 Ciba Ltd Process for the manufacture of bcg vaccines
BR9808441A (pt) * 1997-03-28 2000-05-23 Cytoclonal Pharmaceutics Inc Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura.
BRPI0709106B8 (pt) * 2006-03-24 2021-05-25 Univ Zaragoza vacina contra tuberculose
CN104324365B (zh) * 2014-10-24 2016-03-16 孙二琳 重组人干扰素-α-2b-BCG的干粉剂制备方法
ES2615512B1 (es) 2015-11-06 2018-03-15 Universidad De Zaragoza Dispositivo y sistema microfluídico para el estudio de cultivos celulares
ES2626237B1 (es) 2015-12-22 2018-05-03 Universidad De Zaragoza Sistema electrónico de potencia modular variable para la generación de pulsos eléctricos y usos asociados
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
ES2679721B1 (es) 2017-01-18 2019-06-21 Univ Zaragoza Generador de aerosoles nanoparticulados y procedimiento de generacion de aerosoles en continuo asociado a dicho generador
ES2738926A1 (es) 2018-07-26 2020-01-27 Univ Zaragoza Granulisina, metodo de obtencion y usos

Also Published As

Publication number Publication date
CA3091304A1 (en) 2019-08-22
AU2019221709B2 (en) 2024-04-18
JP2021514392A (ja) 2021-06-10
EP3755374B1 (en) 2023-11-15
EP4233912A3 (en) 2023-11-01
US20240382575A1 (en) 2024-11-21
WO2019158779A1 (en) 2019-08-22
AU2019221709A1 (en) 2020-10-15
US20230165948A1 (en) 2023-06-01
CN112449604B (zh) 2023-05-26
AU2024203034A1 (en) 2024-05-30
EP4233912A2 (en) 2023-08-30
JP7388636B2 (ja) 2023-11-29
EP3755374A1 (en) 2020-12-30
EP3755374C0 (en) 2023-11-15
RU2020130786A (ru) 2022-03-21
CN112449604A (zh) 2021-03-05
BR112020016704A2 (pt) 2020-12-15
US11826411B2 (en) 2023-11-28
JP2025160294A (ja) 2025-10-22
CN116751703A (zh) 2023-09-15
JP2023153868A (ja) 2023-10-18
US20230330201A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US20230330201A1 (en) Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
Conlan et al. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization
ES2366622T3 (es) Cepas de bcg recombinante con capacidad potenciada para escapar del endosoma.
Kim et al. Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice
KR20100065243A (ko) 마이코박테리움의 일렉트로포레이션 및 마이코박테리아에서의 항원의 과발현
JP2005538923A (ja) ミコバクテリアワクチン
JP5461776B2 (ja) マイコバクテリウムのエレクトロポレーションおよびマイコバクテリア中における抗原類の過剰発現
ES2433518T3 (es) Vacuna contra la tuberculosis
Blazevic et al. Investigations of TB vaccine-induced mucosal protection in mice
WO2022167360A1 (en) Attenuated african swine fever virus and its use as a vaccine
ES2319527T3 (es) Cepas atenuadas de vibrio cholerae y vacunas liofilizadas que las contienen.
RU2778094C2 (ru) Композиции для применения в качестве профилактического средства для пациентов с риском туберкулезной инфекции или в качестве вторичных средств для лечения пациентов с туберкулезной инфекцией
ES2549366B1 (es) TRIPLE MUTANTE DEL COMPLEJO MYCOBACTERIUM TUBERCULOSIS erp-, phoP- y DIM-
JP4705573B2 (ja) 弱毒細菌生ワクチン
ES2286033T3 (es) Celulas procariotas que producen trehalosa como vacunas.
Brand Trained immunity vaccines: BCG as a tool to combat SARS-CoV-2 and future pandemics
WO2015076656A1 (es) Una cepa de mycobacterium bovis bcg recombinante carente del gen bcg1419c, con capacidad incrementada de formar biopelículas
Heiat et al. Construction and immunogenicity of a genetically mutant of a native Shigella dysenteriae type 1 isolated from an Iranian patient with diarrhea by recombineering